Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9BXI2: Variant p.Gly159Cys

Mitochondrial ornithine transporter 2
Gene: SLC25A2
Feedback?
Variant information Variant position: help 159 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glycine (G) to Cysteine (C) at position 159 (G159C, p.Gly159Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help Reduces ornithine transport activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 159 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 301 The length of the canonical sequence.
Location on the sequence: help EMEMSGKIAKSHNTIWSVVK G ILKKDGPLGFYHGLSSTLLQ The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 301 Mitochondrial ornithine transporter 2
Repeat 104 – 197 Solcar 2
Mutagenesis 179 – 179 Q -> H. Does not significantly change the substrate specificity.
Mutagenesis 179 – 179 Q -> K. Does not significantly change the substrate specificity.
Mutagenesis 179 – 179 Q -> N. Does not significantly change the substrate specificity.
Mutagenesis 179 – 179 Q -> R. Ornithine homo-exchange is enhanced 18-fold. Vmax value 33-fold higher than wild-type.



Literature citations
Cloning and characterization of human ORNT2: a second mitochondrial ornithine transporter that can rescue a defective ORNT1 in patients with the hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, a urea cycle disorder.
Camacho J.A. III; Rioseco-Camacho N.; Andrade D.; Porter J.; Kong J.;
Mol. Genet. Metab. 79:257-271(2003)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANTS CYS-159 AND GLY-181; CHARACTERIZATION OF VARIANTS CYS-159 AND GLY-181; FUNCTION; SUBCELLULAR LOCATION; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT CYS-159;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.